Janus Kinase Inhibitor for Anti-Transcription Intermediary Factor 1-Γ Positive Cancer-Associated Dermatomyositis
Wanlong Wu,Jinju Chen,Linling Zhu,Yaping Sha,Kaiwen Wang,Jiangfeng Zhao,Chunhua Ye,Shuang Ye
DOI: https://doi.org/10.1093/bjd/ljad396
2024-01-01
Abstract:In this retrospective case series, off-label use of Janus kinase inhibitor rapidly and significantly ameliorated the active cutaneous disease in all five glucocorticoid-resistant patients with cancer-associated dermatomyositis who had anti-transcription intermediary factor 1-γ antibodies, showing a promising steroid-sparing effect and a generally well-tolerated safety profile beyond 1-year follow-up.
What problem does this paper attempt to address?